Viyash Scientific Limited (VIYASH) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated August 06, 2026 3 min read

Viyash Scientific Limited enters its Q1 FY27 results following a year of significant merger integration and balance sheet deleveraging that saw the company reach a 0.2x net debt/EBITDA ratio. Investors will be focused on whether the company can maintain its 20%+ EBITDA margin sustainability and demonstrate progress toward its double-digit growth targets for the API and CDMO segments.

Quick Details

Results date	August 11, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 919.96 Cr
Previous quarter PAT	Rs. 66.38 Cr
Previous quarter EBITDA margin	21.7%
Net debt (latest quarter)	0.2x Net Debt/EBITDA
Market cap	Rs. 11922.3 Cr
CMP	Rs. 272.65

Viyash Scientific Limited Q1 Results Date and Time

The board meeting is scheduled for August 11, 2026, to consider the audited financial results.

The earnings call is scheduled for August 12, 2026, at 3:30 PM IST with the MD & Group CEO, ED, and CFO as speakers.

What to expect from Viyash Scientific Limited's Q1 FY27 results

Viyash Scientific is expected to report revenue growth ahead of the Q1 FY26 base of Rs. 794.1 Cr, supported by its European animal health portfolio and an industry-wide 13.59% expansion in bulk drug exports. While Q1 is seasonally the lowest quarter for animal health, the company's focus on high-margin formulations and the scaling CDMO business, which is projected to grow 30-40% in FY27, provides a constructive outlook for margin sustainability. Management has previously indicated that a 20%+ EBITDA margin is sustainable, though reported figures may face noise from Ind AS 29 hyperinflation adjustments in Turkey, which saw 32.6% annual inflation as of June 2026. The upcoming call will likely address the realization of Rs. 7 Cr in quarterly synergies from site divestments and the status of regulatory clearances for the BioForLife Italia acquisition.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against key FY27 growth and margin targets.

Revenue trajectory — Rs. 4,000 Cr target by FY28 — Q4 FY26 run rate implies Rs. 3,680 Cr annualised
EBITDA margin — 20% sustainable — Q4 FY26 margin was 21.7%
API growth — Double-digit target for FY27 — Q4 FY26 growth was 5% YoY
Innovator/CDMO business — 30-40% growth target for FY27 — Base was Rs. 200-225 Cr in FY26

Strategic and Operational Updates: Monitoring integration benefits and expansion milestones.

Merger synergies — Rs. 7 Cr per quarter savings from site divestment expected to materialise in FY27
BioForLife Italia acquisition — Pending Italian Golden Power clearance required for Q2 FY27 closing
Working capital — Monitoring receivables trend following FY26 consumption of Rs. 3,291.7 Mn

Risks and headwinds to monitor: External factors impacting the reported financials.

Turkey hyperinflation — Ind AS 29 adjustment trend likely higher than the Rs. 18.9 Cr recorded in Q4 FY26
SEBI warning — Remediation status for PIT regulation compliance regarding the Structured Digital Database

Frequently Asked Questions

How is Viyash Scientific planning to grow its CDMO business?

The company is focusing on life cycle management for innovator companies in the animal health sector, where 70-80% of the market consists of innovators. Management expects this segment to grow 30-40% in FY27.

What is the status of the BioForLife Italia acquisition?

Alivira Animal Health executed a sale and purchase agreement on July 21, 2026, to acquire 100% of the entity for approximately Rs. 188 Cr. The transaction is currently pending Italian Golden Power regulatory clearance.

Is Viyash Scientific's revenue growing?

Revenue grew 19.1% YoY in Q4 FY26 to Rs. 919.96 Cr, compared to 8.7% YoY growth in the Q1 FY26 base. This growth is supported by a product mix shift toward high-margin formulations and expansion in European and emerging markets.